Applied Therapeutics’ rare disease drug has failed another late-stage clinical trial, adding to the woes of a candidate that ...

Detailed price information for Applied Therapeutics Inc (APLT-Q) from The Globe and Mail including charting and trades.

Govorestat failed to meet its primary endpoint in a Phase II/III trial for a rare form of Charcot-Marie-Tooth disease, a few ...

NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company”), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for ...

Applied Therapeutics, Inc.’s APLT share price has dipped by 6.65%, which has investors questioning if this is right time to ...

The outcome of the review has come as a major disappointment for patients and their families, with the Galactosemia Foundation calling the outcome "devastating" and urging the FDA to "reconsider ...

The decision not to approve the drug was met with consternation by the Galactosemia Foundation, which represents patients with the disorder, and which called the outcome "devastating." There are ...

But at Wellstar Kennestone Hospital, fresh-faced nurses have a secret weapon: Melanie Copeland. As the hospital’s nurse residency coordinator, Copeland is their steadying force, calming nerves, ...